ASCO GU 2018: Impact of Metastatic Local Treatment in the Strategy of Metastatic Renal Cell Carcinoma Including Stereotactic Radiotherapy, Surgery, and Radiofrequency in an Expert Center.

San Francisco, CA ( Standard of care for patients with metastatic renal cell carcinoma (mRCC) remains systemic therapy with targeted therapy and cytoreductive nephrectomy, though even the nephrectomy has been called into question in the era of targeted therapy.

ASCO GU 2018: Abiraterone or Docetaxel in Men with Metastatic Castration-sensitive Prostate Cancer: A Pooled Analysis of Castration Resistance-free Survival and Toxicity

San Francisco, CA ( The management of metastatic prostate cancer (PCa) continues to change in rapid succession. While we were once reliant on androgen-deprivation therapy for hormone-sensitive prostate cancer (hsPCa) and docetaxel alone for the treatment of metastatic castration-resistant PCa (mCRPC), the landscape of PCa treatment has drastically changed.

ASCO GU 2018: Interim Results from PURE-01: A Phase 2, Open-Label Study of Neoadjuvant Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma

San Francisco, CA ( invasive urothelial bladder cancer (MIUC) is an aggressive disease with more than 40% of patients developing recurrence after radical cystectomy (RC). Despite the fact that there is level 1 evidence demonstrating that cisplatin-based neoadjuvant chemotherapy confers an overall survival benefit1, it is administered in a minority of patients worldwide. Pembro is an EMA and FDA-approved standard therapy for metastatic urothelial carcinoma after platinum failure or for cisplatin-ineligible patients. The authors hypothesized that neoadjuvant pembro, could downstage MIUC and reduce recurrence.

ASCO GU 2018: Real-world Study of Enzalutamide and Abiraterone Acetate (with Prednisone) Tolerability (REAAcT): Results

San Francisco, CA ( Oral enzalutamide and abiraterone (coadministered with prednisone), both androgen axis inhibitors introduced in the past decade, have had an immediate impact on the management of advanced prostate cancer. Approved for men with metastatic castration-resistant prostate cancer, demonstrating significant PFS, CCS and OS benefit, they have become commonly used in this setting.

ASCO GU 2018: Survival Outcomes of Pre-Metastatic Castration-Resistant Prostate Cancer and the Burden of Developing Metastasis: A Systematic Literature Review

San Francisco, CA ( Medical castration, or more rarely surgical castration, has become the mainstay of therapy for metastatic prostate cancer following definitive primary therapy or for de novo metastatic disease. However, unfortunately, all men eventually develop resistance and progress.

ASCO GU 2018: An Observational Study Profiling Biospecimens from 10,000 Metastatic Prostate Cancer Patients to Screen for Molecular Alterations

San Francisco, CA ( Despite recent success in development and use of targeted agents in patients with solid tumors, there is a paucity of such therapies approved for use in prostate cancer (PC). The authors presented this observational study performing next-generation sequencing (NGS) to men with metastatic PC, in an attempt to evaluate the proportion of patients available for targeted therapy clinical trials in metastatic PC. Furthermore, they aimed to assess the feasibility of using a large-scale NGS screening program to match patients for eligibility criteria in clinical trials.

ASCO GU 2018: A Randomized Phase III Double-Blind Clinical Trial (S1600) Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

San Francisco, CA ( This phase III trial will compare the impact of consuming Specialized IMmuno-nutrition (SIM) to oral nutritional support on postoperative complications after radical cystectomy. SIM is fortified with nutrients (L-arginine, omega-3 fatty acids, dietary nucleotides, and vitamin A), that have been shown to have immediate effects on immune and inflammatory responses, muscle sparing, and wound healing after surgery.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.